BR112022025026A2 - Ensaio baseado em células para determinar atividade de morte tumoral in vitro de células imunitárias que expressam antigénio quimérico - Google Patents
Ensaio baseado em células para determinar atividade de morte tumoral in vitro de células imunitárias que expressam antigénio quiméricoInfo
- Publication number
- BR112022025026A2 BR112022025026A2 BR112022025026A BR112022025026A BR112022025026A2 BR 112022025026 A2 BR112022025026 A2 BR 112022025026A2 BR 112022025026 A BR112022025026 A BR 112022025026A BR 112022025026 A BR112022025026 A BR 112022025026A BR 112022025026 A2 BR112022025026 A2 BR 112022025026A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- immune cells
- car
- chimeric antigen
- cells expressing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ENSAIO BASEADO EM CÉLULAS PARA DETERMINAR ATIVIDADE DE MORTE TUMORAL IN VITRO DE CÉLULAS IMUNITÁRIAS QUE EXPRESSAM ANTÍGENO QUIMÉRICO. A presente invenção refere-se a um método in vitro para determinar a potência (por exemplo, citotoxicidade) de uma célula imunitária que expressa uma molécula de recetor de antigénio quimérico (CAR). Na amostra de teste, células imunes que expressam CAR são incubadas com células alvo que expressam um antígeno que interage com o CAR. Em uma amostra de controle, as células imunes que expressam CAR são incubadas com as células alvo e uma molécula inibidora que impede a interação entre o CAR e as células alvo. A quantidade de morte de células alvo é determinada tanto na amostra de teste quanto na amostra de controle e é comparada.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063036249P | 2020-06-08 | 2020-06-08 | |
US202063125173P | 2020-12-14 | 2020-12-14 | |
PCT/IB2021/054996 WO2021250552A1 (en) | 2020-06-08 | 2021-06-07 | Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022025026A2 true BR112022025026A2 (pt) | 2023-02-14 |
Family
ID=76708258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022025026A BR112022025026A2 (pt) | 2020-06-08 | 2021-06-07 | Ensaio baseado em células para determinar atividade de morte tumoral in vitro de células imunitárias que expressam antigénio quimérico |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220057381A1 (pt) |
EP (1) | EP4162269A1 (pt) |
JP (1) | JP2023530238A (pt) |
KR (1) | KR20230022964A (pt) |
CN (1) | CN115917317A (pt) |
AU (1) | AU2021288751A1 (pt) |
BR (1) | BR112022025026A2 (pt) |
CA (1) | CA3186600A1 (pt) |
MX (1) | MX2022015611A (pt) |
WO (1) | WO2021250552A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024097800A1 (en) * | 2022-11-01 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
WO2013126720A2 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing |
US9371396B2 (en) | 2012-06-15 | 2016-06-21 | Sinomab Bioscience Limited | Anti-CD22 anti-idiotypic antibodies and uses thereof |
EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
HUE054588T2 (hu) | 2014-04-07 | 2021-09-28 | Novartis Ag | Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával |
PL3183268T3 (pl) | 2014-08-19 | 2020-09-07 | Novartis Ag | Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego |
AU2016277121C1 (en) * | 2015-06-12 | 2022-07-14 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
WO2018111340A1 (en) * | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
CN108315305B (zh) * | 2017-12-26 | 2020-11-06 | 沣潮医药科技(上海)有限公司 | 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用 |
US11266690B2 (en) * | 2018-02-01 | 2022-03-08 | Nanjing Iaso Biotherapeutics Co., Ltd. | Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof |
WO2020051345A1 (en) * | 2018-09-05 | 2020-03-12 | Memorial Sloan-Kettering Cancer Center | Pleural effusion-based methods for assessing immunoresponsive cell activity |
-
2021
- 2021-06-07 EP EP21736374.6A patent/EP4162269A1/en active Pending
- 2021-06-07 MX MX2022015611A patent/MX2022015611A/es unknown
- 2021-06-07 BR BR112022025026A patent/BR112022025026A2/pt unknown
- 2021-06-07 JP JP2022575355A patent/JP2023530238A/ja active Pending
- 2021-06-07 WO PCT/IB2021/054996 patent/WO2021250552A1/en active Application Filing
- 2021-06-07 KR KR1020237000624A patent/KR20230022964A/ko active Search and Examination
- 2021-06-07 CA CA3186600A patent/CA3186600A1/en active Pending
- 2021-06-07 AU AU2021288751A patent/AU2021288751A1/en active Pending
- 2021-06-07 US US17/340,296 patent/US20220057381A1/en active Pending
- 2021-06-07 CN CN202180049139.3A patent/CN115917317A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230022964A (ko) | 2023-02-16 |
MX2022015611A (es) | 2023-04-18 |
JP2023530238A (ja) | 2023-07-14 |
CN115917317A (zh) | 2023-04-04 |
EP4162269A1 (en) | 2023-04-12 |
CA3186600A1 (en) | 2021-12-16 |
US20220057381A1 (en) | 2022-02-24 |
WO2021250552A1 (en) | 2021-12-16 |
AU2021288751A1 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fallarini et al. | Expression of functional GPR35 in human iNKT cells | |
Ju et al. | H2S-induced S-sulfhydration of pyruvate carboxylase contributes to gluconeogenesis in liver cells | |
Kwon et al. | Discovery of predictive biomarkers for litter size in boar spermatozoa | |
BR112018070823A2 (pt) | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. | |
Houde et al. | Intestinal epithelial cell differentiation involves activation of p38 mitogen-activated protein kinase that regulates the homeobox transcription factor CDX2 | |
Byun et al. | GSK3 inactivation is involved in mitochondrial complex IV defect in transforming growth factor (TGF) β1-induced senescence | |
Laprise et al. | Human homolog of disc-large is required for adherens junction assembly and differentiation of human intestinal epithelial cells | |
Li et al. | Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E | |
Park et al. | Hypoxia induces glucose uptake and metabolism of adipose‑derived stem cells | |
Tamura et al. | AAA peroxins and their recruiter Pex26p modulate the interactions of peroxins involved in peroxisomal protein import | |
Iñesta-Vaquera et al. | Alternative ERK5 regulation by phosphorylation during the cell cycle | |
Srivastava et al. | Regulation of mitochondrial protein import by the nucleotide exchange factors GrpEL1 and GrpEL2 in human cells | |
Tarique et al. | Plasmodium falciparum DOZI, an RNA helicase interacts with eIF4E | |
BR112017004773A2 (pt) | biomarcadores para avaliar câncer de mama | |
Khandelwal et al. | CD38brightCD8+ T cells associated with the development of acute GVHD are activated, proliferating, and cytotoxic trafficking cells | |
BR112014019277A8 (pt) | Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica | |
BR112022009290A2 (pt) | Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 | |
Mareddy et al. | Proteomic profiling of distinct clonal populations of bone marrow mesenchymal stem cells | |
BR112022025026A2 (pt) | Ensaio baseado em células para determinar atividade de morte tumoral in vitro de células imunitárias que expressam antigénio quimérico | |
Kelley et al. | Advanced aging causes diaphragm functional abnormalities, global proteome remodeling, and loss of mitochondrial cysteine redox flexibility in mice | |
Fong-Ngern et al. | Prolonged K+ deficiency increases intracellular ATP, cell cycle arrest and cell death in renal tubular cells | |
Edwards-Hicks et al. | Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function | |
Nishida et al. | Expression of adenosine A2b receptor in rat type II and III taste cells | |
Nguyen et al. | Activation of both protein kinase A (PKA) type I and PKA type II isozymes is required for retinoid-induced maturation of acute promyelocytic leukemia cells | |
Wang et al. | A ternary complex comprising FAK, PTPα and IP3 receptor 1 functionally engages focal adhesions and the endoplasmic reticulum to mediate IL-1-induced Ca2+ signalling in fibroblasts |